argenx Secures FDA Clearance for VYVGART Prefilled Syringe in Myasthenia Gravis and CIDP
Argenx announces FDA approval of VYVGART (efgartigimod) for self-injection in generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy. VYVGART is now available in a prefilled syringe for self-injection, expanding treatment options for patients with these autoimmune disorders.